Novartis
Xolair gets FDA approval for skin condition
March 24, 2014Research and Development, Sales and Marketing FDA, Novartis, Roche, Sanofi, Xolair, chronic hives, csu
An asthma drug developed by Roche subsidiary Genentech and Novartis has been granted an additional indication to treat chronic hives …
Major new launches for 2014
March 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AbbVie, Big Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, ask, johnson, lilly, top 10
AbbVie AbbVie needs a blockbuster to eventually replace its flagship Humira – and is hoping its new hepatitis C treatments …
Novartis extends trial transparency
February 27, 2014Medical Communications, Research and Development, Sales and Marketing EFPIA, EMA, Goldacre, Novartis, alltrials, transparency
Novartis has become the latest pharmaceutical company to allow greater scrutiny of its clinical trial data.
Novartis to axe Horsham site
February 27, 2014Manufacturing and Production, Research and Development, Sales and Marketing Horsham, Novartis, closure, cuts, research, restructure
Novartis has confirmed that it will cease all of its pharmaceutical operations at its Horsham, West Sussex site this year. …
Skin cancer pill shows ‘significant’ response
February 20, 2014Research and Development, Sales and Marketing LDE225, Novartis, bolt, skin cancer, smo
Novartis is celebrating after its investigational pill targeting the most common form of skin cancer met its primary endpoint in …
Police raid Novartis Tokyo office
February 20, 2014Medical Communications, Sales and Marketing Diovan, Japan, Novartis, tokyo
Authorities in Japan have raided the premises of Novartis’ Tokyo operation as part of an ongoing investigation into the promotion …
Novartis pays out for US biotech
February 17, 2014Research and Development, Sales and Marketing Cancer, Novartis, Vaccine, costim pharmaceuticals
Novartis is looking to shore up its cancer immunotherapy pipeline with the purchase of oncology specialist CoStim Pharmaceuticals. The Cambridge, …
Sales rise for Novartis
January 30, 2014Sales and Marketing Gleevec, Glivec, Novartis, gilenya, q4, sales
Multiple sclerosis drug Gilenya, with sales rising 62% year-on-year to $1.9 billion, was one of the stars of last year …
Novartis may axe 1,000 jobs in Diovan wake
January 23, 2014Manufacturing and Production, Sales and Marketing Coartem, Diovan, Novartis, cuts
Novartis will shut down a plant in New York State that made heart drug Diovan and malaria treatment Coartem as …
Incyte names former Novartis president as its chief executive
January 14, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Incyte, Novartis, hoppenot
Biopharma firm Incyte has announced that the former president of Novartis Oncology has been named as its president and chief …
Novartis faces Japan probe
January 10, 2014Sales and Marketing Diovan, Japan, Novartis
Novartis is under pressure in Japan where authorities are looking at the way the Swiss firm promoted its blood pressure …
Novartis shuts plant in Canada cutting 300 jobs
December 16, 2013Manufacturing and Production, Sales and Marketing Canada, Novartis, Ontario, cuts, lens, manufacturing
Novartis is shutting down its manufacturing plant in Canada which will result in 300 people losing their jobs at the …
€16 million fines for J&J and Novartis
December 12, 2013Medical Communications, Sales and Marketing EU, J&J, JJ, Novartis, Sandoz, fentanyl, fines
The European Commission has slapped multi-million euro fines on Johnson & Johnson and Novartis for what it says were ‘shocking’ …
NICE gives Lucentis more scope
November 27, 2013Sales and Marketing Lucentis, NICE, Novartis, cnv
An undisclosed price cut from Novartis has been enough to swing NICE towards using the manufacturer’s Lucentis in a fourth …
Novartis takes top honours in ISPE facility competition
November 12, 2013Manufacturing and Production Novartis, WHO, foya, holly springs
Novartis’ cell culture facility in the US for the production of influenza vaccines has claimed the top prize in the …
Latest content
FibroFind appoints Lee Borthwick as CEO
